Abstract
The effectiveness of triclosan 1% w v against methicillin-resistant Staphylococcus aureus (MRSA) and its effect on skin were compared with chlorhexidine gluconate 4% w v (‘Hibiclens’) in a 7-week trial. Clinical information of MRSA rates obtained during the previous 10 months and results from earlier user acceptibility trials were included. The average number of new cases of MRSA per week was reduced from 3·4 to 0·14 ( P < 0·0001) in the experimental ward whilst no significant changes occurred in the control ward. Staff reported less skin damage and a higher rate of acceptance with the experimental product. Based on results of the trial, a proposal to introduce triclosan for a 12-month study period has been accepted.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
